Evonik Industries AG (FRA:EVKA)
Germany · Delayed Price · Currency is EUR | Market Cap | 9.91B +42.2% |
| Revenue (ttm) | 14.11B -4.0% |
| Net Income | 121.00M -71.5% |
| EPS | 0.14 -71.7% |
| Shares Out | n/a |
| PE Ratio | 81.88 |
| Forward PE | 12.89 |
| Dividend | 0.31 (2.75%) |
| Ex-Dividend Date | Jun 5, 2026 |
| Volume | 500 |
| Open | 9.95 |
| Previous Close | 10.10 |
| Day's Range | 9.95 - 11.10 |
| 52-Week Range | 5.90 - 11.10 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Evonik Industries AG
Evonik Industries AG operates as a chemicals company in the Asia-Pacific, Europe, the Middle East, Africa, and the Americas. It operates through the Advanced Technologies, Custom Solutions, and Infrastructure segments. The Advanced Technologies segment provides polymers for medical applications; crosslinkers; hydrogen peroxide, a sterilizing agent for cleaning silicon wafers and a bleaching agent for the paper and textile industries; fumed and precipitated silicas and silanes for the automotive, tire, electronics, and cosmetics industries; and ... [Read more]
Financial Performance
In 2025, Evonik Industries AG's revenue was 14.07 billion, a decrease of -7.18% compared to the previous year's 15.16 billion. Earnings were 265.00 million, an increase of 19.37%.
Financial StatementsNews
Germany's RAG Foundation could sell entire Evonik stake
RAG Foundation, the largest shareholder in Evonik , could sell its entire stake in the German chemicals manufacturer, it said on Wednesday.
Evonik rejects BASF offer as too low, sources say
German chemicals maker Evonik has rejected a takeover offer of about €22.15 per share from larger peer BASF as too low, two people familiar with the matter told Reuters on Monday.
Evonik rejects BASF’s EUR 10.3B takeover bid, FT reports
A EUR 10.3B bid by BASF (BASFY) for Evonik (EVKIF) has been rejected as too low to warrant negotiations, setting up a potential takeover battle as Evonik pursues restructuring and…
Evonik rejects $11.7 billion BASF takeover bid, FT reports
Evonik has rejected a €10.3 billion ($11.7 billion) takeover bid from BASF for being too low to warrant formal negotiations or to allow its competitor to carry out due diligence, the Financ...
Chemicals Giant BASF Moves for Rival Evonik
The German company said it entered initial talks over a takeover of smaller peer Evonik, a tie-up that would bolster BASF's dominant position in Europe's chemicals industry.
BASF confirms ‘exploratory work’ for potential acquisition of Evonik
BASF (BASFY) confirms exploratory work with the RAG Foundation and Evonik Industries AG (EVKIF) on a possible acquisition of Evonik. Progress and outcome of the exploratory work is currently open.
Evonik confirms non-binding approach from BASF on potential takeover offer
Evonik (EVKIF) stated: “In response to recent media reports, the Executive Board of Evonik Industries AG confirms that it has received a non-binding approach from BASF (BASFY) SE regarding a…
BASF approaches Evonik about potential takeover, FT reports
BASF (BASFY) has approached Evonik (EVKIF) and its largest shareholder RAG-Stiftung about a potential merger, which could broaden BASF’s geographic and product footprint while accelerating consolidati...
Evonik downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley downgraded Evonik (EVKIF) to Equal Weight from Overweight with a price target of EUR 18, down from EUR 21. The firm cites animal nutrition “mean reversion risk” for…
Evonik price target raised to EUR 22 from EUR 20 at Citi
Citi raised the firm’s price target on Evonik (EVKIF) to EUR 22 from EUR 20 and keeps a Buy rating on the shares.
Evonik Industries AG Earnings Call Transcript: Q2 2026
Q2 2026 saw a 24% year-over-year rise in adjusted EBITDA to €630 million, driven by strong Advanced Technologies and methionine performance. Workforce reductions and portfolio optimization continue, with an upgraded full-year outlook and robust cash generation supporting guidance.
Evonik Industries AG Slides: Q2 2026
Evonik Industries AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Evonik Industries AG Quarterly report: Q2 2026
Evonik Industries AG has published its Q2 2026 quarterly earnings report on August 4, 2026.
Evonik Industries AG Earnings release: Q2 2026
Evonik Industries AG released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Evonik Industries AG Slides: Company presentation
Evonik Industries AG has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Evonik Raises Guidance on Higher Prices, Cost Reductions
Evonik said it raised its guidance for the year on higher prices, higher sales volumes and cost reductions.
Evonik price target raised to EUR 17 from EUR 16 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Evonik (EVKIF) to EUR 17 from EUR 16 and keeps a Buy rating on the shares. The firm sees the company reporting…
Evonik Industries AG Transcript: Investor update
Resilience, sustainability, and innovation are integrated to address global challenges and drive growth. Key initiatives include advanced biosolutions, green hydrogen, and circular economy solutions, supported by a restructured R&D organization and international hubs.
Evonik downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs downgraded Evonik (EVKIF) to Neutral from Buy with a price target of EUR 19, down from EUR 20. The firm made seven rating changes in European chemicals, “positioning…
Evonik price target raised to EUR 20 from EUR 17 at Citi
Citi analyst Sebastian Satz raised the firm’s price target on Evonik (EVKIF) to EUR 20 from EUR 17 and keeps a Buy rating on the shares.
Evonik Industries AG Transcript: AGM 2026
The meeting addressed leadership changes, a challenging financial year, and a shift to a performance-based dividend policy. Strategic initiatives focus on innovation, cost discipline, and green transformation, with continued investment in growth areas.
Evonik downgraded to Underweight from Neutral at JPMorgan
JPMorgan downgraded Evonik (EVKIF) to Underweight from Neutral with a EUR 14 price target as part of a broader sector note on European Chemicals. Mid-term earnings and ROIC outlook remains…
Evonik downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded Evonik (EVKIF) to Equal Weight from Overweight with a price target of EUR 18, up from EUR 17. The firm sees a fair valuation following the post-earnings rally.
Evonik upgraded to Buy from Hold at Jefferies
Jefferies analyst Marcus Dunford-Castro upgraded Evonik (EVKIF) to Buy from Hold with a price target of EUR 20, up from EUR 15.10. The firm citing elevated methionine spreads and the…
Evonik price target raised to EUR 16 from EUR 15 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Evonik (EVKIF) to EUR 16 from EUR 15 and keeps a Hold rating on the shares.